1. Home
  2. AKRO vs GEF Comparison

AKRO vs GEF Comparison

Compare AKRO & GEF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • AKRO
  • GEF
  • Stock Information
  • Founded
  • AKRO 2017
  • GEF 1877
  • Country
  • AKRO United States
  • GEF United States
  • Employees
  • AKRO N/A
  • GEF N/A
  • Industry
  • AKRO Biotechnology: Pharmaceutical Preparations
  • GEF
  • Sector
  • AKRO Health Care
  • GEF
  • Exchange
  • AKRO Nasdaq
  • GEF Nasdaq
  • Market Cap
  • AKRO 3.9B
  • GEF 3.8B
  • IPO Year
  • AKRO 2019
  • GEF N/A
  • Fundamental
  • Price
  • AKRO $54.58
  • GEF $64.89
  • Analyst Decision
  • AKRO Strong Buy
  • GEF Buy
  • Analyst Count
  • AKRO 6
  • GEF 7
  • Target Price
  • AKRO $82.50
  • GEF $73.67
  • AVG Volume (30 Days)
  • AKRO 1.8M
  • GEF 287.4K
  • Earning Date
  • AKRO 08-08-2025
  • GEF 08-27-2025
  • Dividend Yield
  • AKRO N/A
  • GEF 3.32%
  • EPS Growth
  • AKRO N/A
  • GEF N/A
  • EPS
  • AKRO N/A
  • GEF 4.49
  • Revenue
  • AKRO N/A
  • GEF $5,522,800,000.00
  • Revenue This Year
  • AKRO N/A
  • GEF N/A
  • Revenue Next Year
  • AKRO N/A
  • GEF $12.18
  • P/E Ratio
  • AKRO N/A
  • GEF $14.48
  • Revenue Growth
  • AKRO N/A
  • GEF 5.89
  • 52 Week Low
  • AKRO $21.02
  • GEF $48.23
  • 52 Week High
  • AKRO $58.40
  • GEF $73.16
  • Technical
  • Relative Strength Index (RSI)
  • AKRO 68.00
  • GEF 60.87
  • Support Level
  • AKRO $53.05
  • GEF $64.80
  • Resistance Level
  • AKRO $56.49
  • GEF $66.84
  • Average True Range (ATR)
  • AKRO 2.44
  • GEF 1.53
  • MACD
  • AKRO -0.26
  • GEF -0.03
  • Stochastic Oscillator
  • AKRO 86.02
  • GEF 52.71

About AKRO Akero Therapeutics Inc.

Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.

About GEF Greif Inc.

Greif Inc is a producer of industrial packaging products and services with manufacturing facilities located in many countries. It offers a comprehensive line of rigid industrial packaging products, such as steel, fiber, and plastic drums, rigid intermediate bulk containers, closure systems for industrial packaging products, transit protection products, water bottles and remanufactured and reconditioned industrial containers, and services, such as container life cycle management, blending, filling, logistics, warehousing, and other packaging services. The company operates in three reportable business segments including Global Industrial Packaging, Paper Packaging and Services, and Land Management. It operates in USA, Europe, Middle East, Africa and Asia and Other Americas.

Share on Social Networks: